EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses

Bo Wang iD, Bingkun Zhou, Junyu Chen, Xi Sun iD, Wenjuan Yang, Tenghao Yang, Hao Yu iD, Peng Chen, Ke Chen, Xiaodong Huang, Xinxiang Fan, Wang He und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024-04 · 12 (4) · e007808

DOI: 10.1136/jitc-2023-007808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.04.2024. Verfasst von Bo Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China. Hauptthemen laut MEDLINE: Interferon Lambda, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research and Development Program of China, National Natural Science Foundation of China, Guangdong Provincial Clinical Research Center for Urological Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interferons (IFNs) are essential for activating an effective immune response and play a central role in immunotherapy-mediated immune cell reactivation for tumor regression. Type III IFN (λ), related to type I IFN (α), plays a crucial role in infections, autoimmunity, and cancer. However, the direct effects of IFN-λ on the tumor immune microenvironment have not been thoroughly investigated.

Methods

We used mouse MB49 bladder tumor models, constructed a retroviral vector expressing mouse IFN-λ3, and transduced tumor cells to evaluate the antitumor action of IFN-λ3 in immune-proficient tumors and T cell-deficient tumors. Furthermore, human bladder cancer samples (cohort 1, n=15) were used for immunohistochemistry and multiplex immunoflurescence analysis to assess the expression pattern of IFN-λ3 in human bladder cancer and correlate it with immune cells’ infiltration. Immunohistochemistry analysis was performed in neoadjuvant immunotherapy cohort (cohort 2, n=20) to assess the correlation between IFN-λ3 expression and the pathological complete response rate.

Results

In immune-proficient tumors, ectopic Ifnl3 expression in tumor cells significantly increased the infiltration of cytotoxic CD8 + T cells, Th1 cells, natural killer cells, proinflammatory macrophages, and dendritic cells, but reduced neutrophil infiltration. Transcriptomic analyses revealed significant upregulation of many genes associated with effective immune response, including lymphocyte recruitment, activation, and phagocytosis, consistent with increased antitumor immune infiltrates and tumor inhibition. Furthermore, IFN-λ3 activity sensitized immune-proficient tumors to anti-PD-1/PD-L1 blockade. In T cell-deficient tumors, increased Ly6G – Ly6C + I-A/I-E + macrophages still enhanced tumor cell phagocytosis in Ifnl3 overexpressing tumors. IFN-λ3 is expressed by tumor and stromal cells in human bladder cancer, and high IFN-λ3 expression was positively associated with effector immune infiltrates and the efficacy of immune checkpoint blockade therapy.

Conclusions

Our study indicated that IFN-λ3 enables macrophage-mediated phagocytosis and antitumor immune responses and suggests a rationale for using Type III IFN as a predictive biomarker and potential immunotherapeutic candidate for bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon LambdaUrinary Bladder NeoplasmsAnimalsMiceHumansCD8-Positive T-LymphocytesMacrophagesImmunityPhagocytosisTumor Microenvironment

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsMacrophagesPhagocytosisUrinary Bladder Neoplasms

Substanzen

Interferon Lambda

Autor:innen und Institutionen

  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen (Zhongsh…
  • Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China lintx@mail.sysu.edu.cn huangj8@mail.sysu.edu.cn.

ORCID-Profile: Bo Wang, Xi Sun, Hao Yu, Jian Huang

Förderung

  • Research and Development Program of China
  • National Natural Science Foundation of China
  • Guangdong Provincial Clinical Research Center for Urological Diseases
  • Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to Bo Wang
  • Guangdong Medical Science and Technology Research Fund Project

Zitieren

APA

Wang, B., Zhou, B., Chen, J., Sun, X., Yang, W., Yang, T., Yu, H., Chen, P., Chen, K., Huang, X., Fan, X., He, W., Huang, J., & Lin, T. (2024). Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. Journal for ImmunoTherapy of Cancer, 12(4), e007808. https://doi.org/10.1136/jitc-2023-007808

Vancouver

Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T, et al. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. Journal for ImmunoTherapy of Cancer. 2024;12(4):e007808. doi:10.1136/jitc-2023-007808

BibTeX
@article{Wang2024,
  author = {Wang, Bo and Zhou, Bingkun and Chen, Junyu and Sun, Xi and Yang, Wenjuan and Yang, Tenghao and Yu, Hao and Chen, Peng and Chen, Ke and Huang, Xiaodong and Fan, Xinxiang and He, Wang and Huang, Jian and Lin, Tianxin},
  title = {Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {e007808},
  doi = {10.1136/jitc-2023-007808}
}
Kostenlos starten →